Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension

Jung-Min KOH; Dong-Jin CHUNG; Yoon-Sok CHUNG; Moo-Il KANG; In-Ju KIM; Yong-Ki MIN; Han-Jin OH; Il-Hyung PARK; Yil-Seob LEE; Barbara KRAVITZ; Brian WATERHOUSE; Antonio NINO; Lorraine-A FITZPATRICK.
Yonsei Medical Journal ; : 905-914, 2016.
Artículo en Inglés | WPRIM | ID: wpr-63333

Documentos relacionados

  1. Assessment of Denosumab in Korean Postmenopausal Women with Osteoporosis: Randomized, Double-Blind, Placebo-Controlled Trial with Open-Label Extension.
  2. Influence of denosumab on bone mineral density in a severe case of pregnancy-associated osteoporosis.
  3. Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients.
  4. Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension.
  5. Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis.
  6. Modeling-Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab.
  7. The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection.
  8. A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk.
  9. Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk.
  10. [Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice].